United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actelion pharmaceuticals uk ltd - selexipag - tablet - 1.4mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actelion pharmaceuticals uk ltd - selexipag - tablet - 1.6mg

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - bosentan monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - bosentan monohydrate -

Israel - English - Ministry of Health

j-c health care ltd - macitentan - film coated tablets - macitentan 10 mg - macitentan - opsumit ® is an endothelin receptor antagonist (era) indicated for the treatment of pulmonary arterial hypertension (pah, who group i) to delay disease progression. disease progression included: death, initiation of intravenous (iv) or subcutaneous prostanoids or clinical worsening of pah (decreased 6-minute walk distance, worsened pah symptoms and need for additional pah treatment). opsumit also reduced hospitalization for pah.

Israel - English - Ministry of Health

j-c health care ltd - macitentan - film coated tablets - macitentan 10 mg - macitentan - opsumit ® is an endothelin receptor antagonist (era) indicated for the treatment of pulmonary arterial hypertension (pah, who group i) to delay disease progression. disease progression included: death, initiation of intravenous (iv) or subcutaneous prostanoids or clinical worsening of pah (decreased 6-minute walk distance, worsened pah symptoms and need for additional pah treatment). opsumit also reduced hospitalization for pah.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - epoprostenol sodium - powder for solution for infusion - 500microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - epoprostenol sodium - powder for solution for infusion - 1.5mg

Israel - English - Ministry of Health

j-c health care ltd - miglustat - capsules - miglustat 100 mg - miglustat - miglustat - zavesca is indicated for the oral treatment of mild to moderate type i gaucher disease. zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with niemann-pick type c disease.

Israel - English - Ministry of Health

j-c health care ltd - selexipag - film coated tablets - selexipag 1000 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease